Boston, USA — 29 September – 1 October 2026 , The 5th mRNA Process Development & CMC Summit, hosted by Hanson Wade, has recently concluded successfully.

On August 19, Moderna and Merck announced topline results from the Phase III INTerpath-001 study of V940 (intismeran autogene). The study enrolled 1,137 patients with completely resected high-risk Stage IIB-IV melanoma. Compared with Keytruda alone, the combination of V940 and Keytruda met its primary endpoint of recurrence‑free survival (RFS) and the key secondary endpoint of distant metastasis‑free survival (DMFS).

In the industrialization of mRNA vaccines and therapeutics, storage and transportation have always been a critical bottleneck. Conventional mRNA‑LNP formulations require ultra‑low temperature storage at ‑20°C or even ‑80°C, which severely limits their global accessibility.

If 2023 was the year mRNA cancer vaccines rekindled hope, then 2026 is the year that hope has been repeatedly reinforced by clinical data.

The 5th LNP Formulation & Process Development Summit has successfully concluded in Boston, bringing together leading innovators across the global RNA delivery ecosystem. As a CDMO focused on integrated mRNA-LNP solutions, Enorna participated extensively through exhibition showcases, poster presentations, and a featured technical presentation—engaging directly with global leaders advancing the frontier of LNP technologies and therapeutics.